The Effects of Metformin on Cisplatin‐Induced Ototoxicity in Diabetic Patients
Otolaryngology–Head and Neck Surgery · 2025
DOI: 10.1002/ohn.1032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2025. Verfasst von Marc-Elie Nader und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Cisplatin, Metformin, Ototoxicity, Antineoplastic Agents. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Objective
Ototoxicity is an important side effect of cisplatin. Recent animal and in vitro studies suggest metformin may protect hearing, though human studies are lacking. We report the first retrospective clinical study exploring the effects of metformin on cisplatin‐induced ototoxicity. Study Design Retrospective case‐control.
Setting
Tertiary‐care center.
Methods
We reviewed all diabetic patients treated with cisplatin who were enrolled in an auditory monitoring program between January 1, 2000 and December 31, 2018. Patients were grouped according to their use of metformin at the time of chemotherapy. Demographics, oncologic diagnosis and treatment, and prior noise exposure were recorded. Audiometric thresholds were compared before and after chemotherapy. The primary outcome measure was a change in hearing as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). Secondary measures of ototoxicity included changes in hearing using the American Speech‐Language‐Hearing Association (ASHA) and TUNE criteria.
Results
Seventy‐two diabetic patients met the inclusion criteria. Forty‐six patients had taken metformin while on chemotherapy and 26 had not. The proportion of hearing loss as defined by both, CTCAE and ASHA criteria, was more than double in the metformin group relative to the nonmetformin group (CTCAE: 54.4% vs 19.2%, P = .004; ASHA: 62.2% vs 28.0%, P = .003). None of the potential covariates believed to be confounders were significantly associated with the outcome of multivariable analysis.
Conclusion
Contrary to expectations from preclinical data, metformin did not reduce the incidence of hearing loss in patients receiving cisplatin and may, in fact, be associated with an increased risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Austin ENT, Austin, Texas, USA.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Widex US, Weatherford, Texas, USA.
- Department of Otorhinolaryngology-Head and Neck Surgery, McGovern Medical School, UTHealth Houston, Houston, Texas, USA.
- National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, USA.
ORCID-Profile: Marc-Elie Nader, Jonathan Choi, Mike Hernandez, Katherine Hutcheson, Rajarshi Pratihar, Katharine Fernandez, Jack Phan, Paul W Gidley
Zitieren
APA
Nader, M. E., Choi, J., Hernandez, M., Hutcheson, K., Myers, T., Jivani, S., Pratihar, R., Fernandez, K., Phan, J., You, C., & Gidley, P. W. (2025). The Effects of Metformin on Cisplatin‐Induced Ototoxicity in Diabetic Patients. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.1032
Vancouver
Nader ME, Choi J, Hernandez M, Hutcheson K, Myers T, Jivani S, et al. The Effects of Metformin on Cisplatin‐Induced Ototoxicity in Diabetic Patients. Otolaryngology–Head and Neck Surgery. 2025. doi:10.1002/ohn.1032
BibTeX
@article{Nader2025,
author = {Nader, Marc-Elie and Choi, Jonathan and Hernandez, Mike and Hutcheson, Katherine and Myers, Taylor and Jivani, Shirin and Pratihar, Rajarshi and Fernandez, Katharine and Phan, Jack and You, Chelsea and Gidley, Paul W},
title = {The Effects of Metformin on Cisplatin‐Induced Ototoxicity in Diabetic Patients},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2025},
doi = {10.1002/ohn.1032}
}
EUVIMED